Evidence map›Paper›PMID 35715852›Full record

ReviewStem cell research & therapy2022

Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.

Saman Yasamineh, Hesam Ghafouri Kalajahi, Pooneh Yasamineh, Omid Gholizadeh, Hamed Rahmani Youshanlouei, Saeed Karimi Matloub, Masoud Mozafari, Elham Jokar, Yalda Yazdani, Mehdi Dadashpour

Open access · goldAbstract readReview
In one paragraph

Review in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Viruses and neurodegeneration: a growing concern.Journal of translational medicine · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Saman YasaminehDepartment of Medical Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Hesam Ghafouri KalajahiDepartment of Biotechnology, Institute of Science, Uskudar University, Istanbul, Turkey.
Pooneh YasaminehYoung Researchers and Elite Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran.
Omid GholizadehDepartment of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Hamed Rahmani YoushanloueiDepartment of Internal Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Saeed Karimi MatloubStudents Research Committee, Qom University of Medical Sciences, Qom, Iran.
Masoud MozafariCardiovascular Pharmacology Research Lab, Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Elham JokarDepartment of Medical Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Yalda YazdaniImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. yaldayznn@gmail.com.
Mehdi DadashpourCancer Research Center, Semnan University of Medical Sciences, Semnan, Iran. dadashpourm@semums.ac.ir.ORCID 0000-0003-3352-7880
Tabriz University of Medical Sciences · IRIslamic Azad University of Tabriz · IRAhvaz Jundishapur University of Medical Sciences · IRQom University of Medical Science and Health Services · IRSemnan University of Medical Sciences · IRShiraz University of Medical Sciences · IRÜsküdar University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-COV-2 virus has infected the world at a very high rate by causing COVID-19 disease. Nearly 507 million individuals have been infected with this virus, with approximately 1.2% of these patients being dead, indicating that this virus has been out of control in many countries. While researchers are investigating how to develop efficient drugs and vaccines versus the COVID-19 pandemic, new superseded treatments have the potential to reduce mortality. The recent application of mesenchymal stem cells (MSCs) in a subgroup of COVID-19 patients with acute respiratory distress has created potential benefits as supportive therapy for this viral contagion in patients with acute conditions and aged patients with severe pneumonia. Consequently, within this overview, we discuss the role and therapeutic potential of MSCs and the challenges ahead in using them to treat viral infections, with highlighting on COVID-19 infection.

Indexed as

COVID-19Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAgedHumansPandemicsSARS-CoV-2COVID-19Mesenchymal stem cellsSARS-CoV-2Stem cells therapy

Identifiers

PMID35715852
PMCPMC9204679
OpenAlexW4283028584

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.